Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer

Authors: Yingying Cheng, Xiaolin Wang, Pingzhang Wang, Ting Li, Fengzhan Hu, Qiang Liu, Fan Yang, Jun Wang, Tao Xu, Wenling Han

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

Sushi domain containing 2 (SUSD2) is type I membrane protein containing domains inherent to adhesion molecules. There have been few reported studies on SUSD2, and they have mainly focused on breast cancer, colon cancer, and HeLa cells. However, the expression and function of SUSD2 in other cancers remain unclear. In the present study, we conducted an integrated bioinformatics analysis based on the array data from the GEO database and found a significant downregulation of SUSD2 in renal cell carcinoma (RCC) and lung cancer. Western blotting and quantitative RT-PCR (qRT-PCR) confirmed that SUSD2 was frequently decreased in RCC and lung cancer tissues compared with the corresponding levels in normal adjacent tissues. The restoration of SUSD2 expression inhibited the proliferation and clonogenicity of RCC and lung cancer cells, whereas the knockdown of SUSD2 promoted A549 cell growth. Our findings suggested that SUSD2 functions as a tumor suppressor gene (TSG) in RCC and lung cancer.
Literature
1.
Sugahara T, Yamashita Y, Shinomi M, Yamanoha B, Iseki H, Takeda A, et al. Isolation of a novel mouse gene, mSVS-1/SUSD2, reversing tumorigenic phenotypes of cancer cells. Cancer Sci. 2007;6:900–8.CrossRef
2.
Sugahara T, Yamashita Y, Shinomi M, Isobe Y, Yamanoha B, Iseki H, et al. Von Willebrand factor type D domain mutant of Blackwell Publishing Asia SVS-1/SUSD2, vWD(m), induces apoptosis in HeLa cells. Cancer Sci. 2007;6:909–15.CrossRef
3.
Watson AP, Evans RL, Egland KA. Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis. Mol Cancer Res. 2013;11:74–85.CrossRefPubMed
4.
Pan W, Cheng Y, Zhang H, Liu B, Mo X, Li T, et al. CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest. Sci Rep. 2014;4:6812.CrossRefPubMedPubMedCentral
5.
Letouzey V, Tan KS, Deane JA, Ulrich D, Gurung S, Ong YR, et al. Isolation and characterisation of mesenchymal Stem/Stromal cells in the ovine endometrium. Plos One. 2015;10:e0127531.CrossRefPubMedPubMedCentral
6.
Benz K, Stippich C, Freudigmann C, Mollenhauer JA, Aicher WK, et al. Maintenance of “stem cell” features of cartilage cell sub-populations during in vitro propagation. J Transl Med. 2013;11:27.CrossRefPubMedPubMedCentral
7.
Ulrich D, Tan KS, Deane J, Schwab K, Cheong A, Rosamilia A, et al. Mesenchymal stem/stromal cells in post-menopausal endometrium. Hum Reprod. 2014;29:1895–905.CrossRefPubMed
8.
Sivasubramaniyan K, Harichandan A, Schumann S, Sobiesiak M, Lengerke C, Maurer A, et al. Prospective isolation of mesenchymal stem cells from human bone marrow using novel antibodies directed against Sushi domain containing 2. Stem Cells Dev. 2013;22:1944–54.CrossRefPubMed
9.
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. Plos One. 2013;8:e62823.CrossRefPubMedPubMedCentral
10.
11.
12.
Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012;10:859–80.CrossRefPubMedPubMedCentral
13.
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–71.CrossRefPubMed
14.
15.
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMed
16.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
17.
Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J, et al. MiR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. Onco Targets Ther. 2015;8:1773–83.CrossRefPubMedPubMedCentral
18.
Wang P, Qi H, Song S, Li S, Huang N, Han W, et al. ImmuCo: a database of gene co-expression in immune cells. Nucleic Acids Res. 2015;43:D1133–9.CrossRefPubMed
19.
20.
Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69:5194–201.CrossRefPubMed
21.
Li T, Cheng Y, Wang P, Wang W, Hu F, Mo X, et al. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma. J Exp Clin Canc Res. 2015;34:122.CrossRef
22.
23.
24.
Metadata
Title
SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer
Authors
Yingying Cheng
Xiaolin Wang
Pingzhang Wang
Ting Li
Fengzhan Hu
Qiang Liu
Fan Yang
Jun Wang
Tao Xu
Wenling Han
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4734-y

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer

Original Article

Upregulation of p-Smad2 contributes to FAT10-induced oncogenic activities in glioma

Original Article

B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway

Original Article

miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas

Original Article

Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients

Original Article

High risk of development of renal cell tumor in end-stage kidney disease: the role of microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits